Skip to main content
Erschienen in: Clinical Reviews in Allergy & Immunology 3/2018

11.04.2016

A Comprehensive Overview of the Hereditary Periodic Fever Syndromes

verfasst von: Donato Rigante, Bruno Frediani, Luca Cantarini

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Innate immunity is a critical partner in the regulation of inflammation and some mutations in genes implied in innate immunity pathways can cause genetic disorders characterized by seemingly unprovoked self-limited inflammatory attacks. These rare conditions are collectively named “hereditary periodic fever syndromes” (HPFS), and protean pathogenetic mechanisms combined with several clinical phenotypes characterize at least four distinct conditions: (1) familial Mediterranean fever, which is the prototype and the most widely recognized among HPFS, inherited as an autosomal recessive disorder showing recurrent dysregulated inflammatory processes, caused by an abnormal interaction between cytoskeleton and inflammasome, a key-signaling platform that releases interleukin-1β (IL-1β); (2) the group of cryopyrin-associated periodic syndrome, which upsets directly the production of IL-1β, with a dominant pattern of inheritance; (3) tumor necrosis factor receptor-associated periodic syndrome, which is an autosomal dominant disorder subverting the functions and traffic of a cell membrane protein; and (4) mevalonate kinase deficiency, which is an autosomal recessive metabolic disorder halting the biosynthesis of cholesterol. MEFV, NLRP3, TNFRSF1A, and MVK are respectively the four causing genes of these conditions, all resulting in excessive IL-1β signaling, though the encoded proteins act at different levels in cytoskeletal filament organization, apoptosis, and activation of the IL-1β-structured inflammasome. The differential diagnosis of HPFS can be challenging, as there are no universally accepted diagnostic algorithms, and near half of patients may have a specific disease without any genetic pathogenetic variant identified. Herein, we outline the most relevant aspects of HPFS at the crossroads between clinical medicine and immunology and all the most recent advances in their treatment, as the increasing use of IL-1 antagonists has achieved unexpected clinical results in a large number of patients.
Literatur
2.
Zurück zum Zitat Dzik JM (2010) The ancestry and cumulative evolution of immune reactions. Acta Biochim Pol 57(4):443–466PubMed Dzik JM (2010) The ancestry and cumulative evolution of immune reactions. Acta Biochim Pol 57(4):443–466PubMed
7.
Zurück zum Zitat Cantarini L, Lopalco G, Cattalini M, Vitale A, Galeazzi M, Rigante D (2015) Interleukin-1: ariadne’s thread in autoinflammatory and autoimmune disorders. Israel Med Assoc J 17(2):93–97 Cantarini L, Lopalco G, Cattalini M, Vitale A, Galeazzi M, Rigante D (2015) Interleukin-1: ariadne’s thread in autoinflammatory and autoimmune disorders. Israel Med Assoc J 17(2):93–97
8.
Zurück zum Zitat Auron PE, Webb AC, Rosenwasser LJ, Mucci SF, Rich A, Wolff SM, Dinarello CA (1984) Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci U S A 81(24):7907–7911CrossRefPubMedPubMedCentral Auron PE, Webb AC, Rosenwasser LJ, Mucci SF, Rich A, Wolff SM, Dinarello CA (1984) Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci U S A 81(24):7907–7911CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Mariathasan S, Monack DM (2007) Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol 7(1):31–40CrossRefPubMed Mariathasan S, Monack DM (2007) Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol 7(1):31–40CrossRefPubMed
10.
Zurück zum Zitat Vitale A, Rigante D, Lucherini OM et al (2013) Biological treatments: new weapons in the management of monogenic autoinflammatory disorders. Mediat Inflamm 2013:939847. doi:10.1155/2013/939847 CrossRef Vitale A, Rigante D, Lucherini OM et al (2013) Biological treatments: new weapons in the management of monogenic autoinflammatory disorders. Mediat Inflamm 2013:939847. doi:10.​1155/​2013/​939847 CrossRef
11.
12.
Zurück zum Zitat Centola M, Wood G, Frucht DM et al (2000) The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood 95(10):3223–3231PubMed Centola M, Wood G, Frucht DM et al (2000) The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood 95(10):3223–3231PubMed
15.
Zurück zum Zitat Balci B, Tinaztepe K, Yilmaz E et al (2002) MEFV gene mutations in familial Mediterranean fever phenotype II patients with renal amyloidosis in childhood: a retrospective clinicopathological and molecular study. Nephrol Dial Transplant 17(11):1921–1923CrossRefPubMed Balci B, Tinaztepe K, Yilmaz E et al (2002) MEFV gene mutations in familial Mediterranean fever phenotype II patients with renal amyloidosis in childhood: a retrospective clinicopathological and molecular study. Nephrol Dial Transplant 17(11):1921–1923CrossRefPubMed
17.
Zurück zum Zitat Livneh A, Langevitz P, Zemer D et al (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40(10):1879–1885CrossRefPubMed Livneh A, Langevitz P, Zemer D et al (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40(10):1879–1885CrossRefPubMed
20.
Zurück zum Zitat Rigante D, La Torraca I, Avallone L, Pugliese AL, Gaspari S, Stabile A (2006) The pharmacological basis of treatment with colchicine in children with familial Mediterranean fever. Eur Rev Med Pharmacol Sci 10(4):173–178PubMed Rigante D, La Torraca I, Avallone L, Pugliese AL, Gaspari S, Stabile A (2006) The pharmacological basis of treatment with colchicine in children with familial Mediterranean fever. Eur Rev Med Pharmacol Sci 10(4):173–178PubMed
22.
Zurück zum Zitat Aksentijevich I, Galon J, Soares M et al (2001) The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet 69(2):301–314CrossRefPubMedPubMedCentral Aksentijevich I, Galon J, Soares M et al (2001) The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet 69(2):301–314CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Cantarini L, Rigante D, Merlini G et al (2014) The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: clinical manifestations and long-term follow-up. Semin Arthritis Rheum 43(6):818–823. doi:10.1016/j.semarthrit.2013.12.002 CrossRefPubMed Cantarini L, Rigante D, Merlini G et al (2014) The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: clinical manifestations and long-term follow-up. Semin Arthritis Rheum 43(6):818–823. doi:10.​1016/​j.​semarthrit.​2013.​12.​002 CrossRefPubMed
25.
27.
Zurück zum Zitat Stojanov S, McDermott MF (2005) The tumour necrosis factor receptor-associated periodic syndrome: current concepts. Expert Rev Mol Med 7(22):1–18CrossRefPubMed Stojanov S, McDermott MF (2005) The tumour necrosis factor receptor-associated periodic syndrome: current concepts. Expert Rev Mol Med 7(22):1–18CrossRefPubMed
29.
Zurück zum Zitat Ravet N, Rouaghe S, Dodé C et al (2006) Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene. Ann Rheum Dis 65(9):1158–1162CrossRefPubMedPubMedCentral Ravet N, Rouaghe S, Dodé C et al (2006) Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene. Ann Rheum Dis 65(9):1158–1162CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Aksentijevich I, D Putnam C, Remmers EF et al (2007) The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 56(4):1273–1285CrossRefPubMedPubMedCentral Aksentijevich I, D Putnam C, Remmers EF et al (2007) The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 56(4):1273–1285CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Cantarini L, Lucherini OM, Frediani B et al (2011) Bridging the gap between the clinician and the patient with cryopyrin-associated periodic syndromes. Int J Immunopathol Pharmacol 24(4):827–836CrossRefPubMed Cantarini L, Lucherini OM, Frediani B et al (2011) Bridging the gap between the clinician and the patient with cryopyrin-associated periodic syndromes. Int J Immunopathol Pharmacol 24(4):827–836CrossRefPubMed
32.
Zurück zum Zitat Tanaka N, Izawa K, Saito MK et al (2011) High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: results of an International Multicenter Collaborative Study. Arthritis Rheum 63(11):3625–3632. doi:10.1002/art.30512 CrossRefPubMedPubMedCentral Tanaka N, Izawa K, Saito MK et al (2011) High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: results of an International Multicenter Collaborative Study. Arthritis Rheum 63(11):3625–3632. doi:10.​1002/​art.​30512 CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Hoffman HM, Wanderer AA, Broide DH (2001) Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol 108(4):615–620CrossRefPubMedPubMedCentral Hoffman HM, Wanderer AA, Broide DH (2001) Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol 108(4):615–620CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Aganna E, Martinon F, Hawkins PN et al (2002) Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum 46(9):2445–2452CrossRefPubMed Aganna E, Martinon F, Hawkins PN et al (2002) Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum 46(9):2445–2452CrossRefPubMed
35.
Zurück zum Zitat Prieur AM, Griscelli C, Lampert F et al (1987) A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patients. Scand J Rheumatol 66:57–68CrossRef Prieur AM, Griscelli C, Lampert F et al (1987) A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patients. Scand J Rheumatol 66:57–68CrossRef
36.
Zurück zum Zitat Rigante D (2010) The protean visage of systemic autoinflammatory syndromes: a challenge for inter-professional collaboration. Eur Rev Med Pharmacol Sci 14(1):1–18PubMed Rigante D (2010) The protean visage of systemic autoinflammatory syndromes: a challenge for inter-professional collaboration. Eur Rev Med Pharmacol Sci 14(1):1–18PubMed
37.
Zurück zum Zitat Esposito S, Ascolese B, Senatore L et al (2014) Current advances in the understanding and treatment of mevalonate kinase deficiency. Int J Immunopathol Pharmacol 27(4):491–498CrossRefPubMed Esposito S, Ascolese B, Senatore L et al (2014) Current advances in the understanding and treatment of mevalonate kinase deficiency. Int J Immunopathol Pharmacol 27(4):491–498CrossRefPubMed
38.
Zurück zum Zitat Mendey SH, Kuijk LM, Frenkel J, Waterham HR (2006) A role for geranylgeranylation in interleukin-1β secretion. Arthritis Rheum 54(11):3690–3695CrossRef Mendey SH, Kuijk LM, Frenkel J, Waterham HR (2006) A role for geranylgeranylation in interleukin-1β secretion. Arthritis Rheum 54(11):3690–3695CrossRef
39.
Zurück zum Zitat Mendey SH, Schneiders MS, Koster J, Waterham HR (2006) Mutational spectrum and genotype-phenotype correlations in mevalonate kinase deficiency. Hum Mutat 27(8):796–802CrossRef Mendey SH, Schneiders MS, Koster J, Waterham HR (2006) Mutational spectrum and genotype-phenotype correlations in mevalonate kinase deficiency. Hum Mutat 27(8):796–802CrossRef
43.
Zurück zum Zitat Ammouri W, Cuisset L, Rouaghe S et al (2007) Diagnostic value of serum immunoglobulinaemia D level in patients with a clinical suspicion of hyper IgD syndrome. Rheumatology (Oxford) 46(10):1597–1600CrossRef Ammouri W, Cuisset L, Rouaghe S et al (2007) Diagnostic value of serum immunoglobulinaemia D level in patients with a clinical suspicion of hyper IgD syndrome. Rheumatology (Oxford) 46(10):1597–1600CrossRef
45.
Zurück zum Zitat Gershoni-Baruch R, Brik R, Zacks N, Shinawi M, Lidar M, Livneh A (2003) The contribution of genotypes at the MEFV and SSA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum 48(4):1149–1155CrossRefPubMed Gershoni-Baruch R, Brik R, Zacks N, Shinawi M, Lidar M, Livneh A (2003) The contribution of genotypes at the MEFV and SSA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum 48(4):1149–1155CrossRefPubMed
50.
Zurück zum Zitat Bulua AC, Mogul DB, Aksentijevich I et al (2012) Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. Arthritis Rheum 64(3):908–913. doi:10.1002/art.33416 CrossRefPubMed Bulua AC, Mogul DB, Aksentijevich I et al (2012) Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. Arthritis Rheum 64(3):908–913. doi:10.​1002/​art.​33416 CrossRefPubMed
51.
Zurück zum Zitat Nedjai B, Hitman GA, Quillinan N et al (2009) Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 60(2):619–625. doi:10.1002/art.24294 CrossRefPubMed Nedjai B, Hitman GA, Quillinan N et al (2009) Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 60(2):619–625. doi:10.​1002/​art.​24294 CrossRefPubMed
53.
Zurück zum Zitat Federico G, Rigante D, Pugliese A, Ranno O, Catania S, Stabile A (2003) Etanercept induces improvement of arthropathy in chronic infantile neurological cutaneous articular (CINCA) syndrome. Scand J Rheumatol 32(5):312–314CrossRefPubMed Federico G, Rigante D, Pugliese A, Ranno O, Catania S, Stabile A (2003) Etanercept induces improvement of arthropathy in chronic infantile neurological cutaneous articular (CINCA) syndrome. Scand J Rheumatol 32(5):312–314CrossRefPubMed
55.
Zurück zum Zitat Rigante D, Ansuini V, Caldarelli M, Bertoni B, La Torraca I, Stabile A (2006) Hydrocephalus in CINCA syndrome treated with anakinra. Childs Nerv Syst 22(4):334–337CrossRefPubMed Rigante D, Ansuini V, Caldarelli M, Bertoni B, La Torraca I, Stabile A (2006) Hydrocephalus in CINCA syndrome treated with anakinra. Childs Nerv Syst 22(4):334–337CrossRefPubMed
56.
Zurück zum Zitat Kuemmerle-Deschner JB, Hachulla E, Cartwright R et al (2011) Two-years results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 70(12):2095–2102. doi:10.1136/ard.2011.152728 CrossRefPubMed Kuemmerle-Deschner JB, Hachulla E, Cartwright R et al (2011) Two-years results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 70(12):2095–2102. doi:10.​1136/​ard.​2011.​152728 CrossRefPubMed
59.
Zurück zum Zitat Koné-Paut I, Lachmann HJ, Kuemmerle-Deschner JB et al (2011) Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res Ther 13:R202. doi:10.1186/ar3535 CrossRefPubMedPubMedCentral Koné-Paut I, Lachmann HJ, Kuemmerle-Deschner JB et al (2011) Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res Ther 13:R202. doi:10.​1186/​ar3535 CrossRefPubMedPubMedCentral
60.
Zurück zum Zitat Anton J, Calvo I, Fernández-Martin J et al (2015) Efficacy and safety of canakinumab in cryopyrin-associated periodic syndromes: results from a Spanish cohort. Clin Exp Rheumatol 33(6 Suppl 94):S67–71PubMed Anton J, Calvo I, Fernández-Martin J et al (2015) Efficacy and safety of canakinumab in cryopyrin-associated periodic syndromes: results from a Spanish cohort. Clin Exp Rheumatol 33(6 Suppl 94):S67–71PubMed
61.
Zurück zum Zitat Steichen O, van der Hilst J, Simon A, Cuisset L, Grateau G (2009) A clinical criterion to exclude the hyperimmunoglobulin D syndrome (mild mevalonate kinase deficiency) in patients with recurrent fever. J Rheumatol 36(8):1677–1681. doi:10.3899/jrheum.081313 CrossRefPubMed Steichen O, van der Hilst J, Simon A, Cuisset L, Grateau G (2009) A clinical criterion to exclude the hyperimmunoglobulin D syndrome (mild mevalonate kinase deficiency) in patients with recurrent fever. J Rheumatol 36(8):1677–1681. doi:10.​3899/​jrheum.​081313 CrossRefPubMed
63.
Zurück zum Zitat Galeotti C, Meinzer U, Quartier P et al (2012) Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency. Rheumatology (Oxford) 51(10):1855–1859CrossRef Galeotti C, Meinzer U, Quartier P et al (2012) Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency. Rheumatology (Oxford) 51(10):1855–1859CrossRef
64.
Zurück zum Zitat Neven B, Valayannopoulos V, Quartier P et al (2007) Allogeneic bone marrow transplantation in mevalonic aciduria. N Engl J Med 356(26):2700–2703CrossRefPubMed Neven B, Valayannopoulos V, Quartier P et al (2007) Allogeneic bone marrow transplantation in mevalonic aciduria. N Engl J Med 356(26):2700–2703CrossRefPubMed
Metadaten
Titel
A Comprehensive Overview of the Hereditary Periodic Fever Syndromes
verfasst von
Donato Rigante
Bruno Frediani
Luca Cantarini
Publikationsdatum
11.04.2016
Verlag
Springer US
Erschienen in
Clinical Reviews in Allergy & Immunology / Ausgabe 3/2018
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-016-8537-8

Weitere Artikel der Ausgabe 3/2018

Clinical Reviews in Allergy & Immunology 3/2018 Zur Ausgabe

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.